Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure.

J Cardiovasc Dev Dis

Silesian Center for Heart Diseases, Third Department of Cardiology, Faculty of Medical Science in Zabrze, Medical University of Silesia, 41-800 Zabrze, Poland.

Published: July 2022

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are currently the second-line pharmacotherapy in type 2 diabetes, particularly through their effectiveness in reducing glycemia, but also due to their cardioprotective and nephroprotective effects. In light of surprisingly satisfactory results from large, randomized trials on gliflozins, SGLT2 received the highest recommendation (Class IA) with the highest level of evidence (A) in the treatment algorithm for HF with reduced LVEF in recent ESC HF guidelines. This great breakthrough in the treatment of HF is due to different mechanisms of action of gliflozins that are reported to be able to change the natural course of HF by reducing the risk of both hospitalization and death. They are recommended regardless of the patient's diabetes status. This review summarizes the up-to-date literature on their beneficial and pleiotropic impact on the cardiovascular system.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325125PMC
http://dx.doi.org/10.3390/jcdd9070225DOI Listing

Publication Analysis

Top Keywords

sodium-glucose cotransporter-2
8
cotransporter-2 inhibitors-from
4
inhibitors-from treatment
4
treatment diabetes
4
diabetes therapy
4
therapy chronic
4
chronic heart
4
heart failure
4
failure sodium-glucose
4
cotransporter-2 sglt2
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!